Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Diana Rose E Ranoa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Carl R. Woese Institute for Genomic Biology and Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Ovarian Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Gerald O. Mann Foundation, Harriet and Allan Wulfstat.
Abstract (Originalsprache)
Background
Treatment of some blood cancers with T cells that express a chimeric antigen receptor (CAR) against CD19 have shown remarkable results. In contrast, CAR-T cell efficacy against solid tumors has been difficult to achieve.
Methods
To examine the potential of CAR-T cell treatments against ovarian cancers, we used the mouse ovarian cancer cell line ID8 in an intraperitoneal model that exhibits disseminated solid tumors in female C57BL/6J mice. The CAR contained a single-chain Fv from antibody 237 which recognizes a Tn-glycopeptide-antigen expressed by ID8 due to aberrant O-linked glycosylation in the absence of the transferase-dependent chaperone Cosmc . The efficacy of four Tn-dependent CARs with varying affinity to Tn antigen, and each containing CD28/CD3ζ cytoplasmic domains, were compared in vitro and in vivo in this study.
Results
In line with many observations about the impact of aberrant O-linked glycosylation, the ID8 Cosmc knock-out (ID8 Cosmc -KO) exhibited more rapid tumor progression compared with wild-type ID8. Despite the enhanced tumor growth in vivo, 237 CAR and a mutant with 30-fold higher affinity, but not CARs with lower affinity, controlled advanced ID8 Cosmc -KO tumors. Tumor regression could be achieved with a single intravenous dose of the CARs, but intraperitoneal administration was even more effective. The CAR-T cells persisted over a period of months, allowing CAR-treated mice to delay tumor growth in a re-challenge setting. The most effective CARs exhibited the highest affinity for antigen. Antitumor effects observed in vivo were associated with increased numbers of T cells and macrophages, and higher levels of cleaved caspase-3, in the tumor microenvironment. Notably, the least therapeutically effective CAR mediated tonic signaling leading to antigen-independent cytokine expression and it had higher levels of the immunosuppressive cytokine interleukin10.
Conclusion
The findings support the development of affinity-optimized CAR-T cells as a potential treatment for established ovarian cancer, with the most effective CARs mediating a distinct pattern of inflammatory cytokine release in vitro. Importantly, the most potent Tn-dependent CAR-T cells showed no evidence of toxicity in tumor-bearing mice in a syngeneic, immunocompetent system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Carl R. Woese Institute for Genomic Biology and Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department of Pathology and David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, Illinois, USA.
- Charles River Laboratories Inc Mattawan, Mattawan, Michigan, USA.
ORCID-Profile: Diana Rose E Ranoa, Amber N Lewis, David M Kranz
Förderung
- NCI NIH HHS
- Gerald O. Mann Foundation
- Harriet and Allan Wulfstat
- NIH
Zitieren
APA
Ranoa, D. R. E., Sharma, P., Schane, C. P., Lewis, A. N., Valdez, E., Marada, V. V. V. R., Hager, M. V., Montgomery, W., Wolf, S. P., Schreiber, K., Schreiber, H., Bailey, K., Fan, T. M., Hergenrother, P. J., Roy, E. J., & Kranz, D. M. (2023). Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006509
Vancouver
Ranoa DRE, Sharma P, Schane CP, Lewis AN, Valdez E, Marada VVVR, et al. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006509
BibTeX
@article{Ranoa2023,
author = {Ranoa, Diana Rose E and Sharma, Preeti and Schane, Claire P and Lewis, Amber N and Valdez, Edward and Marada, Venkata V V R and Hager, Marlies V and Montgomery, Will and Wolf, Steven P and Schreiber, Karin and Schreiber, Hans and Bailey, Keith and Fan, Timothy M and Hergenrother, Paul J and Roy, Edward J and Kranz, David M},
title = {Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006509}
}
EUVIMED